To evaluate if DNAJA2-deficiency enhances ICB efficacy, we injected WT or DNAJA2-depleted 4T1 or B16-OVA cells subcutaneously into immunocompetent mice, and monitored the tumor growth after treating tumors with or without ICB antibodies. Here, DNAJA2 is linked to neoplasm.